Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (231-240 of 323) with videos related to

Pageof 33
Sort By:
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
Blood Advances|October 2, 2019
<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaJoshua N Gustine, Lian Xu, Nicholas Tsakmaklis, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Pageof 33

Showing results (231-240 of 323) with videos related to

Sort By:
Pageof 33
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
Blood Advances|October 2, 2019
<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaJoshua N Gustine, Lian Xu, Nicholas Tsakmaklis, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Pageof 33